Literature DB >> 2180588

Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril.

H Hirakata1, F M Fouad-Tarazi, F M Bumpus, M Khosla, B Healy, A Husain, H Urata, H Kumagai.   

Abstract

We examined the hypothesis that the positive inotropic effect of angiotensin I (Ang I) may be retained in the presence of angiotensin converting enzyme inhibitors so that it may have a direct beneficial effect on the heart. Accordingly, isolated perfused hearts (Langendorff preparation) of 300-day-old cardiomyopathic hamsters (a model of spontaneous cardiomyopathy) and age-matched normal hamsters (controls) were infused with Ang I in the presence of captopril; propranolol was added to the perfusing medium to block catecholamine-mediated effects of angiotensins on the heart. Left ventricular developed pressure and the rate of increase in left ventricular developed pressure increased significantly (p less than 0.001) in both the cardiomyopathic and the normal hamster heart despite concomitant reduction in myocardial flow rate favoring a direct inotropic effect of Ang I in both normal and myopathic hearts; these changes were significantly higher by almost threefold in the cardiomyopathic than in the normal hamsters (p less than 0.01) and were blocked by the angiotensin II (Ang II) antagonist [Sar1,Thr8]Ang II. Comparing dose-left ventricular contractility response curves for Ang I and Ang II, ED50 for responses was identical in both normal and myopathic hearts, whereas peak responses to Ang II were double those to Ang I in normal hearts but were almost identical in the myopathic hearts. Binding of [125I]Ang II in six cardiomyopathic and four normal hamster hearts was of high affinity, but there was no evidence for Ang I-saturable high-affinity binding sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180588     DOI: 10.1161/01.res.66.4.891

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

1.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

2.  Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.

Authors:  H Schunkert; V J Dzau; S S Tang; A T Hirsch; C S Apstein; B H Lorell
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

3.  Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy.

Authors:  N Makino; M Sugano; T Hata; S Taguchi; T Yanaga
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

Review 4.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

5.  Cardiac haemodynamic effects of the non-peptide, angiotensin II-receptor antagonist, DuP 753, in conscious Long Evans and Brattleboro rats.

Authors:  P Batin; S M Gardiner; A M Compton; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

Review 6.  Risks and benefits of the treatment of heart failure. Current status.

Authors:  J F Moran
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 7.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03

8.  Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart.

Authors:  I Pörsti; M Hecker; E Bassenge; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

9.  Protective effects of aspirin from cardiac hypertrophy and oxidative stress in cardiomyopathic hamsters.

Authors:  Rong Wu; David Yin; Nataliya Sadekova; Christian F Deschepper; Jacques de Champlain; Helene Girouard
Journal:  Oxid Med Cell Longev       Date:  2012-07-04       Impact factor: 6.543

Review 10.  The Angiotensin-(1-12)/Chymase axis as an alternate component of the tissue renin angiotensin system.

Authors:  Carlos M Ferrario; Leanne Groban; Hao Wang; Che Ping Cheng; Jessica L VonCannon; Kendra N Wright; Xuming Sun; Sarfaraz Ahmad
Journal:  Mol Cell Endocrinol       Date:  2020-12-10       Impact factor: 4.369

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.